Homogenous Entropy-Driven Biomolecular Assay (HEBA)

Tech ID: 27455 / UC Case 2015-579-0

Summary

Professors in the UCLA Department of Bioengineering have developed a novel short oligonucleotide assay to fluorescently detect biomolecules.

Background

The ability to quickly and accurately detect biomolecules indicative of disease is crucial given importance of early diagnosis in disease treatment. The current gold-standard in the field of biomolecule detection is the enzyme-linked immunosorbent assay or ELISA, however, current ELISA-based diagnostic assays suffer from various limitations. ELISA assays require a significant number of sample preparation and wash steps which are a hindrance to their use in point-of-care (POC) diagnostic settings; their use in clinical microbiology settings or high throughput screens requires significant automation and remains robotics-intensive. Additionally, immunoassays currently available for the detection of specific analytes suffer from sensitivity issues as they lack signal amplification. Therefore, there remains a need for novel diagnostic assays with increased sensitivity, decreased overall sample preparation and handling, and greater usability for POC diagnostic settings.

Innovation

Professor Di Carlo and colleagues have developed a novel biomolecule detection assay utilizing small oligonucleotides which immediately generates signal in the presence of a specific analyte. HEBA is a single-pot assay capable of detecting the presence of a biomolecule in relevant bio fluids at room temperature in 10 minutes. HEBA overcomes multiple limitations of current molecule detection assays as it does not require washing steps or temperature cycling, is enzyme independent, does not require immobilization at a surface, and is sensitive to the attomolar range in a microfluidic digital assay platform. Compared to current assay methods HEBA improves the level of detection of analyte, is performed as a homogeneous assay and requires only ten minutes for detection.

Applications

  • Molecular diagnostics
  • Research tools
  • On-site monitoring/point-of-care systems

Advantages

  • Excludes several limiting factors of other assays (surface immobilization, thermocycling, enzymes)
  • Homogeneous, single-pot reaction (i.e. removes washing steps, decreases assay time)
  • Increased level of sensitivity (aM compared to pM (typical of ELISA assays))  
  • Robust in variety of liquids (including whole blood and plasma)

State Of Development

To date the technology has demonstrated efficacy in detecting influenza biomolecules in relevant buffers, whole blood and undiluted plasma.

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20180179576 06/28/2018 2015-579
 

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Di Carlo, Dino

Other Information

Keywords

biomolecular assay, oligonucleotide sequence assay, analyte recognition, immunoassay, molecular detection, diagnostic assay, fluorescent, fluorescence

Categorized As